Scaffold platform | Structure | Size | Development stage | Antigenic components displayed | Expression system | Reference |
---|---|---|---|---|---|---|
PCV2 VLP | Icosahedral symmetry (60 subunits) | 25 nm | Licensed (Porcilis PCV® and Ingelvac CircoFLEX1®) | CSFV E2 | BEVS/E. Coli | Liu et al. 2022; Li et al. 2021; Jung et al. 2020a; Ding et al. 2019 |
PRRSV GP5Â (epitope B and epitope 7) | E. Coli | |||||
PRRSV GP3/GP5 | BEVS | |||||
H1N1 M2e | E. Coli | |||||
RHDV VLP | Icosahedral symmetry (180 subunits) | 40Â nm | Preclinical | RHDV VP60 | E. Coli | Guo et al. 2016; Dalton et al. 2021; Rangel et al. 2021; Crisci et al. 2012 |
Chimeric two RHDV VP60 | BEVS | |||||
FMDV VP1 and 3A | BEVS | |||||
FMDV 3A | BEVS | |||||
FMDV VLP | Icosahedral symmetry (60 subunits) | 30Â nm | Preclinical | FMDV VP0, VP1Â and VP3 | E. Coli | |
Chimeric two FMDV Cap | BEVS | |||||
PPV VLP | Icosahedral symmetry (60 subunits) | 25Â nm | Preclinical | PPV VP2 | E. Coli | |
PPV VP2 and PCV2 Cap | E. Coli | |||||
JEV E | E. Coli | |||||
SIV VLP | spherical symmetry | Depend on type | Clinical trials | H1N1 and H3N2 HA-M1 | BEVS | |
H1N1 and H3N2 HA-M1 | BEVS | |||||
H3N2 NA and H1N1 M1 | BEVS |